Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

NovoTTF Treatment Signatures in Glioblastoma Patients at Autopsy

NCT: NCT03194971 · COMPLETED

NCT IDNCT03194971
StatusCOMPLETED
Start Date2017-06-01
Completion2023-06-04

Brief Summary

This study will assess whole brain samples from glioblastoma patients at autopsy to determine the underlying pathological signatures of tumor treatment fields at autopsy.

Frequently Asked Questions

What is NovoTTF Treatment Signatures in Glioblastoma Patients at Autopsy?

NovoTTF Treatment Signatures in Glioblastoma Patients at Autopsy is a clinical trial registered under NCT03194971. Current status: COMPLETED.

What is the status of NCT03194971?

The current status of NCT03194971 (NovoTTF Treatment Signatures in Glioblastoma Patients at Autopsy) is: COMPLETED.

When did NovoTTF Treatment Signatures in Glioblastoma Patients at Autopsy start?

NovoTTF Treatment Signatures in Glioblastoma Patients at Autopsy started on 2017-06-01.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑